20 results about "Glycoprotein binding" patented technology

The invention related to a method for selective enrichment of glycoproteins from a sample comprising proteins, the method comprising: —determining the concentration of proteins in the sample or providing the sample with a defined concentration of proteins; incubating particles in the sample to form a protein corona comprising glycoproteins bound to the surface of the particles, wherein the protein concentration to the total surface area of the particles is selected, and / or the particle material is selected, in order to enrich for a specific glycoprotein species on the protein corona; and optionally isolating the protein corona from the sample; and associated methods of screening for biomarkers and diagnosis, and associated compositions.

The present disclosure provides antibodies and antigen-binding fragments that are capable of binding to RSV and / or MPV fusion glycoproteins and that are capable of neutralizing RSV and / or MPV infection. Also provided are polynucleotides encoding the antibodies, vectors comprising such polynucleotides, host cells capable of expressing these antibodies, related compositions, and methods of using the compositions disclosed herein, for example, to treat or prevent RSV and / or MPV infection.

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition for preventing pneumococcal and varicella-zoster virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition. The immunogenic composition of the present invention comprises: at least one pneumococcal polysaccharide-protein conjugate wherein the pneumococcal polysaccharide is linked to a carrier protein through a covalent bond; the carrier protein is varicella-zoster virus glycoprotein E, namely VZV gE recombinant protein, and the amino acid sequence of the VZV gE recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. The immunogenic composition containing the multivalent pneumococcal polysaccharide-protein conjugate, provided by the invention, shows a remarkable synergistic interaction effect, and realizes a'dual enhancement 'effect.

The present disclosure relates to asiaglycoprotein (ASGPR) binding elements, ASGPR binding complexes having one or more ASGPR binding elements, and protein-targeting constructs having one or more ASGPR binding elements and one or more target protein recognition elements. The ASGPR binding elements, ASGPR binding complexes, and protein-targeting constructs are generally useful for hepatocyte-targeting therapies, which may include degradation of the target protein. The disclosure also relates to methods of treating various diseases in a mammal, including protein-associated diseases and more particularly diseases associated with the production, overproduction, or accumulation of a target protein in a cell or tissue.

The present disclosure provides antibodies and antigen-binding fragments that are capable of binding to RSV and / or MPV fusion glycoproteins and that are capable of neutralizing RSV and / or MPV infection. Also provided are polynucleotides encoding the antibodies, vectors comprising such polynucleotides, host cells capable of expressing these antibodies, related compositions, and methods of using the compositions disclosed herein, for example, to treat or prevent RSV and / or MPV infection.

The present invention describes a (first) anti-HSV antibody or antigen-binding fragment thereof that binds to glycoprotein B (gB) of HSV-1 and / or HSV-2 wherein the antibody comprises complementarity determining regions VHCDR1, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, each comprising a sequence defined in the claims wherein the antibody or antigen-binding fragment has a sequence of at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 a low dissociation rate kdis of up to 5.0 x 10 <-5 > s <-1 > and most preferably up to 2.9 x 10 <-5 > s <-1 >. In addition, the present invention also describes a combination of (A) the (first) anti-HSV antibody or antigen-binding fragment thereof; and (B) a second anti-HSV antibody or antigen-binding fragment thereof that recognizes / binds to glycoprotein B (gB) of HSV-1 and / or HSV-2 wherein the antibody comprises complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, each comprising the sequences defined in the claims wherein the second antibody has a dissociation constant Kd of at most 40 nM, preferably at most 30 nM, more preferably at most 20 nM, even more preferably at most 15 nM, at most 13 nM and at most 10 nM. Furthermore, the present invention also describes a pharmaceutical composition comprising an effective amount of said anti-HSV antibody or antigen-binding fragment thereof, or a combination of said antibodies, and at least one pharmaceutically acceptable excipient. Furthermore, the present invention also describes an anti-HSV antibody or antigen binding fragment thereof or said combination of said antibodies for use in a method of prophylactic or therapeutic treatment of a disorder or disease as defined in the claims. Furthermore, the present invention also describes a bispecific antibody that binds to glycoprotein B (gB) of HSV-1 and / or HSV-2, comprising: (A) a first binding domain comprising: complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3 of the aforementioned first antibody; and (B) a second binding domain comprising: complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 of the aforementioned second antibody; wherein the bispecific antibody has a low dissociation rate kdis of at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, at most 5.0 x 10 <-5 > s <-1 >, most preferably at most 2.9 x 10 <-5 > s <-1 >. Finally, the present invention describes a trispecific antibody comprising a third binding domain in addition to the first binding domain and the second binding domain as described for the bispecific antibody.

Provided are a pneumococcal conjugate combined vaccine and a preparation method therefor. The combination comprises 26 different pneumococcal polysaccharide-protein conjugates, and the pneumococcal polysaccharide comprises a total of 26 serotypes, i.e., 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 24F, 33F and 35B. The carrier protein used by the conjugate is tetanus toxoid (TT). The polysaccharide is covalently linked to the TT by means of a cyano activation method so as to prepare a polysaccharide-protein conjugate stock solution, and the polysaccharide-protein conjugate stock solution is then adsorbed by an aluminum adjuvant in an appropriate proportion so as to obtain the pneumococcal conjugate vaccine. The pneumococcal polysaccharide used therein requires no degradation reaction, effectively protecting the antigenicity of the polysaccharide. Three consecutive batches of production of the conjugate stock solution and vaccine are performed, and the yield and each verification index of the conjugate are stable. The results of non-clinical safety evaluation research show that the vaccine has good safety and immunogenicity. The prepared pneumococcal conjugate vaccine is used for immunoprophylaxis of pneumococcal infection of relevant serotypes.

The invention provides construction of a universal influenza virus fluorescent molecular imprinting sensor and a method for visually detecting influenza viruses. In the invention, a zeolite imidazolate skeleton (ZIF-8) coated red fluorescent quantum dots (R-QDs) is used as an imprinting carrier and signal output, influenza virus H7N9 is used as a template, and the molecularly imprinted polymer (MIPs) is prepared by a sol-gel technology. Meanwhile, the surfaces of the magnetic Fe3O4 nanoparticles are modified with phenylboronic acid (Fe3O4-FPBA) to serve as a capture element, and when the H7N9 virus is specifically bound with the MIPs, Fe3O4-FPBA can be bound with glycoprotein on the surface of the virus through boric acid esterification reaction, so that a sandwich composite structure of MIPs-virus-Fe3O4-FPBA is formed. Through the formation of the structure, separation and enrichment of a target object can be realized through a magnet, and meanwhile, the change of a quantum dot fluorescence signal is caused, so that visual detection of a target virus is realized, and high-sensitivity quantitative detection can also be performed through an ultraviolet and visible spectrophotometer. The sensor prepared by the invention is a general influenza virus sensor, and the fluorescent sensor suitable for visually detecting other target objects can be prepared by selecting other subtype influenza viruses as template molecules for molecular imprinting.

The present invention relates to antibody molecules and functional fragments thereof capable of binding to human glycoprotein VI (GPVI), methods for their production and therapeutic uses thereof.

The present application relates to the technical field of biotechnology, in particular to a kind of multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition for preventing pneumococcus and varicella-zoster virus infection and its preparation method and application.The immunogenic composition of the present application comprises:at least one pneumococcal polysaccharide-protein conjugate, wherein the pneumococcal polysaccharide is connected with carrier protein by covalent bond;The carrier protein is varicella-zoster virus glycoprotein E, i.e.VZV gE recombinant protein, and its amino acid sequence is shown as SEQ ID NO:3 or SEQ ID NO:4.The immunogenic composition containing multivalent pneumococcal polysaccharide-protein conjugate provided by the present application shows significant synergistic effect, realizes "double enhancement" effect.

(A first) anti-HSV antibody or an antigen-binding fragment thereof that binds to glycoprotein B (gB) of HSV-1 and / or HSV-2, wherein the antibody comprises complementarity-determining regions V each containing the sequences defined in the claims H CDR1, V H CDR3, V L CDR1, V L CDR2, and V L CDR3, and wherein the antibody or its antigen-binding fragment has a maximum dissociation rate k -4 s -1 of at most 5.0 x 10 -4 s -1 preferably at most 1.0 x 10 -5 s -1 most preferably at most 2.9 x 10 -5 s -1 is described. Further, (A) the (first) anti-HSV antibody or its antigen-binding fragment, and (B) a second anti-HSV antibody or its antigen-binding fragment that recognizes / binds to glycoprotein B (gB) of HSV-1 and / or HSV-2, wherein the antibody comprises complementarity-determining regions V each containing the sequences defined in the claims dis CDR1, V H CDR1, V H CDR2, V H CDR3, V L CDR1, V L CDR2, and V LA combination of a second anti-HSV antibody or its antigen-binding fragment is described, comprising CDR3, wherein the second antibody has a dissociation constant Kd of up to 40 nM, preferably up to 30 nM, more preferably up to 20 nM, even more preferably up to 15 nM, up to 13 nM, and up to 10 nM. Furthermore, a pharmaceutical composition is described comprising an effective amount of the anti-HSV antibody or its antigen-binding fragment, or the combination of the antibodies, and at least one pharmaceutically acceptable excipient. Furthermore, the anti-HSV antibody or its antigen-binding fragment or the combination of the antibodies is described for use in a method for the prophylactic or therapeutic treatment of a disorder or disease as defined in the claims. Furthermore, (A) V, which is the complementarity-determining region of the first antibody described above. H CDR1, V H CDR2, V H CDR3, V L CDR1, V L CDR2, and V L (B) The first binding domain containing CDR3 and (B) the complementarity determining region of the second antibody described above. H CDR1, V H CDR2, V H CDR3, V L CDR1, V L CDR2, and V L A bispecific antibody that binds to glycoprotein B(gB) of HSV-1 and / or HSV-2, comprising a second binding domain containing CDR3, with a maximum capacity of 5.0 x 10⁻¹⁴. -4 s -1 Preferably a maximum of 1.0 x 10 -4 s -1 , up to 5.0x10 -5 s -1 Most preferably a maximum of 2.9 x 10 -5 s -1 A bispecific antibody having a low dissociation rate of kdis is described. Finally, a triplicate antibody is described that includes a third binding domain in addition to the first and second binding domains described for the bispecific antibody.

The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.

Disclosed is a method for detecting whether a biological sample (e.g., serum, blood, plasma) contains an antibody against SARS-CoV-2 S glycoprotein, the method comprising: (i) providing a surface coated with SARS-CoV-2 S glycoprotein; (ii) exposing the surface to the biological sample; (iii) exposing the surface to a secondary antibody; and (iv) detecting the secondary antibody bound to the surface; wherein if a secondary antibody is detected, the biological sample contains an antibody that binds to the SARS-CoV-2 S glycoprotein.

Described herein are antibodies or antigen-binding fragments that bind to the O-glycan mucin-type glycoprotein MUC16, comprising three variable heavy domain complementarity-determining regions (CDRs) (CDRs H1, H2, and H3) and three variable light domain CDRs (CDRs L1, L2, and L3). The present invention also relates to pharmaceutical compositions, nucleic acid vectors, cells containing the nucleic acid vectors, and methods for inhibiting tumor growth of tumors expressing the O-glycan mucin-type glycoprotein MUC16.

The invention relates to a traditional Chinese medicine compound feed additive for improving animal absorption and meat quality as well as a preparation method and application of the traditional Chinese medicine compound feed additive. The traditional Chinese medicine compound feed additive is prepared from an intestinal tract conditioning group and an intestinal tract conditioning group, wherein the intestinal tract conditioning group comprises 10-20 parts of bighead atractylodes rhizome, 8-15 parts of poria cocos, 12-20 parts of medicated leaven and 10-20 parts of Chinese yam; a digestion promoting group: 10-18 parts of hawthorn and 10-18 parts of malt; the immunity enhancing group comprises 8-15 parts of astragalus membranaceus and 8-12 parts of codonopsis pilosula; and a meat quality improving group: 6-12 parts of dried orange peel and 5-10 parts of liquorice. The additive disclosed by the invention is combined with glycoprotein in gastrointestinal mucous membrane to play a role in protecting the gastrointestinal mucous membrane, rapidly repairing damaged mucous membrane, promoting mucous membrane regeneration and improving the defense capability of the gastrointestinal mucous membrane, so that the non-specific immunity and the anti-stress capability of an organism are improved; the traditional Chinese medicine composition can promote mitosis of intestinal epithelial cells and growth of intestinal villi, improve the absorption capacity of intestinal tracts to nutrient substances, accelerate gastric emptying, reduce the occurrence of excessive gastric acid caused by rumination pressure of rumen, repair damage to gastrointestinal mucosa and epithelial tissues, promote integrity of gastrointestinal structures and functions and maintain gastrointestinal flora balance.

The present invention relates to combination vaccine comprising hexavalent serogroup of Neisseria meningitidis for prevention and prophylaxis of infection caused by meningococcal bacteria. The present invention relates to a hexavalent combination vaccine comprising serogroups A, B, C, Y, W, X of Neisseria meningitidis. The present invention relates to a hexavalent combination vaccine comprising polysaccharide- protein conjugate of serogroups A, C, Y, W, X and proteins of serogroup B of Neisseria meningitidis. The present invention specifically relates to a hexavalent combination vaccine comprising polysaccharide- protein conjugate of serogroup A, C, Y, W, X and mutated Factor H binding proteins (fHbp) of serogroup B of Neisseria meningitidis. The present invention further relates to the composition, use and process of preparation of hexavalent combination vaccine.

An immunogenic vaccine composition comprising a bivalent polysaccharide-protein conjugate vaccine comprising a Salmonella enterica serovar typhi saccharide-carrier protein and a Salmonella enterica se

The present invention discloses the preparation of a pneumococcal conjugate combination vaccine, belonging to the technical field of biopreparation. The composition includes 26 different pneumococcal polysaccharide-protein conjugates. The pneumococcal polysaccharides include 26 serotypes, namely 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 24F, 33F and 35B. The carrier protein used in the conjugate is tetanus toxoid (TT). The polysaccharide-protein conjugate stock solution is prepared by covalently binding the polysaccharide and TT through a cyanide activation method. The polysaccharide-protein conjugate stock solution is then adsorbed with aluminum adjuvant in an appropriate proportion to obtain the pneumococcal conjugate vaccine. In particular, the pneumococcal polysaccharides used in the present invention do not need to undergo a degradation reaction, effectively protecting the antigenicity of the polysaccharide. The production of three consecutive batches of conjugate stock solution and vaccine is carried out, and the conjugate yield and various verification indexes are stable. The results of non-clinical safety evaluation studies show that the vaccine has good safety and immunogenicity. The pneumococcal conjugate vaccine prepared by the present invention is used for the immunoprevention of pneumococcal infections of related serotypes.

A glycoprotein NMB (GPNMB) binding chimeric antigen receptor (CAR) is provided. In some embodiments, the CARs of the present disclosure comprise an extracellular GPNMB binding domain (e.g., a single chain antibody, such as scFv), a transmembrane domain, and one or more intracellular signaling domains. Nucleic acids and expression constructs encoding such CARs are also provided. Also provided are cells (e.g., immune cells, such as T cells) comprising the nucleic acids and the expression constructs. Aspects of the disclosure further include compositions comprising a population of such cells that express GPNMB binding CARs on their surfaces; and methods of administering such compositions to treat conditions associated with GPNMB expression and / or activity in a subject in need thereof. Non-limiting examples of conditions associated with GPNMB expression and / or activity include cancer (e.g., sarcoma, such as soft tissue sarcoma), neurodegenerative disease, and the like.